Description
Peg is used off-label in colorectal cancer as an adjunct to chemotherapy or immunotherapy; it has shown modest efficacy in clinical trials when combined with other agents, particularly in patients who have progressed on standard treatments; its use is mainly experimental and not yet approved for routine use in CCR.
Mechanism of Action
Peg interferes with DNA replication and transcription in cancer cells, leading to cell cycle arrest and apoptosis; it also enhances the immune response against tumor cells.
Side Effects
Fatigue; neutropenia; thrombocytopenia; fever; chills; myalgias; arthralgias
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT04798612
Phase 2
Unknown
Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression
Denmark
NCT05648318
Not Applicable
Archived
Comparison of Oral Lactulose Versus Polyethylene Glycol for Bowel Preparation in Low-risk Patients
China
NCT03435640
Phase 1
Archived
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
United States
NCT02650635
Phase 1
Archived
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
United States
NCT02481219
Not Applicable
Archived
Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure
United States
NCT02009449
Phase 1
Archived
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
United States